Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06517199
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia However there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy Therefore this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None